Fludrocortisone Acetate Tablets (Aspen) (50455)
Fludrocortisone Acetate Tablets (Aspen) (50455)

The following Competition guidance note provides comprehensive and up to date legal information covering:

  • Fludrocortisone Acetate Tablets (Aspen) (50455)
  • Case facts
  • Timeline
  • Commentary
  • Related cases


See further, timeline, commentary andrelated cases

Case facts

Outline CMA Article 101 TFEU/Chapter I and Article 102 TFEU/Chapter II investigation into Aspen’s alleged breach of competition law in relation to the supply of Fludrocortisone Acetate Tablets in the UK.

Latest developments On 22 January 2020, the CMA announced that Tiofarma and Tioffarma Beheer had admitted to participating in a market-sharing agreement involving Fludrocortisone Acetate Tablets and agreed to pay a maximum fine of £186,422.

Parties • Aspen Pharmacare Holdings Ltd, Aspen Global Inc., Apsen Pharma Ireland Ltd, and Aspen Pharma Trading Ltd (together, Aspen: Aspen is a multinational pharmaceutical group with its headquarters in South Africa. It owns a broad portfolio of branded and generic prescription products that are sold to wholesalers, hospitals and pharmacies in over 100 countries.

• Amilco Limited (Amilco): Amilco is a UK based company that specialise in the sale of medical stock.

• Tiofarma and Tiofarma Beheer (together, Tiofarma: Tiofarma is a Dutch based pharmaceutical company. It develops and produces a wide variety of medicines throughout Europe.